- Medicine Name: Mektovi
- Generic Name: Binimetinib
- Dosage Form & Strength: Tablets: 15 mg
- Manufactured By: Array BioPharma Inc.
Mektovi is a kinase inhibitor used, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.
Recommended Dosage: The recommended dosage of Mektovi Tablet is 45 mg taken by mouth (orally) twice daily, approximately 12 hours apart, in combination with medicine encorafenib until the disease is progressive or unacceptable toxicity occurs.
Tablets may be taken with or without meals. Do not take a missed dose within 6 hours of the next dose of Mektovi.
Do not take any extra dose in case puking occurs after the administration of tablets but continue with the very next scheduled dose.
Note: Confirm the existence of a BRAF V600E or V600K mutation in tumor specimens prior to initiating Mektovi treatment.
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.